ArticleFrontiers in pharmacology2026
Real world pharmacovigilance assessment of drug related perinatal depression risks.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Perinatal depression (PND) is a prevalent and serious mental health concern affecting women during pregnancy and the postpartum period. Although several drugs have been implicated in PND etiology in previous studies, large-scale systematic evaluations of drug-associated PND using real-world pharmacovigilance data remain scarce. Methods: We conducted a retrospective pharmacovigilance study utilizing the FDA Adverse Event Reporting System data spanning from Q1 2004 to Q2 2025. Disproportionality analysis, logistic regression, LASSO regression, and time-to-onset analysis were employed to examine drug-PND associations from multiple analytical perspectives. Results: Disproportionality analyses identified 28 drugs with positive signals as potentially associated with PND. Multi-factor analysis identified age under 26 years, weight exceeding 74 kg, and use of sodium oxybate, levonorgestrel, ethinylestradiol/etonogestrel, or lurasidone as independent risk factors for drug-related PND. The model achieved a ROC-AUC of 0.907, indicating excellent discriminatory performance. Conclusion: This study identified specific drugs and demographic factors associated with PND risk, offering valuable insights for pharmacovigilance and clinical medication management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.